B
1.65
-0.07 (-3.80%)
| Previous Close | 1.71 |
| Open | 1.74 |
| Volume | 74,316 |
| Avg. Volume (3M) | 795,603 |
| Market Cap | 93,209,320 |
| Price / Sales | 3.04 |
| Price / Book | 1.60 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Profit Margin | 7.27% |
| Operating Margin (TTM) | 77.90% |
| Diluted EPS (TTM) | 0.060 |
| Total Debt/Equity (MRQ) | 15.25% |
| Current Ratio (MRQ) | 9.24 |
| Operating Cash Flow (TTM) | 12.31 M |
| Levered Free Cash Flow (TTM) | 10.10 M |
| Return on Assets (TTM) | -0.42% |
| Return on Equity (TTM) | 4.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Black Diamond Therapeutics, Inc | Bearish | Bearish |
AIStockmoo Score
1.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 83.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (HC Wainwright & Co., 507.90%) | Buy |
| Median | 8.00 (386.32%) | |
| Low | 8.00 (Stifel, 386.32%) | Buy |
| 8.00 (Guggenheim, 386.32%) | Buy | |
| Average | 8.67 (427.05%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 3.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 16 Oct 2025 | 8.00 (386.32%) | Buy | 4.18 |
| Guggenheim | 04 Sep 2025 | 8.00 (386.32%) | Buy | 2.87 |
| HC Wainwright & Co. | 11 Aug 2025 | 10.00 (507.90%) | Buy | 2.31 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Aug 2025 | Announcement | Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |